Trial Profile
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eflapegrastim (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 26 Feb 2021 According to a Spectrum Pharmaceuticals media release, a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS (eflapegrastim) from this trial will be presented as part of the 38th Annual Miami Breast Cancer Conference taking place virtually 4th to 7th Mar 2021.
- 12 Aug 2020 Results, analysis of data from 3 trails (one phase II and 2 phase III studies) assessing the fixed dose of Eflapegrastim in patients receiving Docetaxel-Cyclophosphamide chemotherapy, published in the Journal of Clinical Pharmacology
- 27 Dec 2018 Status changed from recruiting to completed.